← All themes

ADC & cancer drugs stocks

ADC·항암제

What are ADC & cancer drugs stocks in Korea?

The ADC & cancer drugs theme on jonbur groups 8 Korean stocks listed on KOSPI and KOSDAQ, worth ₩94T in total. On Oct 28, 2026 the group moved up 0.46% (weighted by market value); the largest members are Samsung Biologics, Alteogen, Yuhan.

Key facts

Stocks
8
Total market value
₩94T
Day's move
+0.46%
As of
Oct 28, 2026
Largest members
Samsung Biologics, Alteogen, Yuhan

Earnings tracker · 3Q 2025

Past quarter

7 of 7 reportedOperating profit up vs a year ago: 3 of 7
Revenue+22.5%
Operating profit+89.8%
Net profit+118.0%

Combined, for the companies that have reported, vs the same quarter a year ago

CompanyReportedRevenuevs a year agoOperating profitvs a year agovs last quarterOp. margin
Samsung BiologicsNov 14₩1.7T+39.9%₩729B+115.3%+53.2%43.9%28.5%
AlteogenNov 14₩49B+902.3%₩27BTurned to profitTurned to profit54.4%−166.8%
YuhanNov 14₩570B−4.8%₩22B−53.7%−55.8%3.9%7.9%
Hanmi PharmNov 14₩362B+0.1%₩55B+8.0%−8.9%15.2%14.1%
LigaChem BiosciencesNov 14₩41B+36.1%−₩23BTurned to lossBigger loss−56.0%1.7%
ABL BioNov 11₩1.4B−81.8%−₩22BBigger lossTurned to loss−1,552.8%−185.1%
OncocrossNov 14₩29M−84.0%−₩2.4BBigger lossBigger loss−8,104.5%−808.7%

Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.

Technical breadth

After the close on Oct 28, 2026
Above 20-day average
20%
Above 60-day average
10%
RSI above 70
0%
RSI below 30
0%
52-week highs
0
52-week lows
0

Index gauge · Short term

Bearish

1 bullish, 1 neutral, 7 bearish

Index gauge · Medium term

Bearish

0 bullish, 1 neutral, 7 bearish

Technical read

The ADC and cancer drugs group comprises 10 members, and 20 of the counted readings show shares above their 20-day averages while 10 sit above their 60-day averages, which leaves the breadth picture split between short-term and medium-term trends. None of the members registered an RSI extreme on either side, and no member recorded a 52-week high or low in the data provided. The equal-weighted member index is labeled bearish on both the short and medium horizons, with its RSI at 41.6 and its price sitting below the cloud.

Written by AI from the indicator values above. Not advice.

Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.

Credit & macro

No notable credit, ELS or macro events for these companies in the last 30 days.

Creators talking about this

ADC & cancer drugs

+1.38%

ADC·항암제

ADC & cancer drugs is a Korean stock-market theme covering antibody-drug conjugates, which link an antibody to a cytotoxic payload to target cancer cells, along with other oncology drug developers and related contract manufacturing and platform technologies. Korean investors tend to group these companies together because the sector is closely tied to biopharma licensing deals with global pharmaceutical firms and to the technology transfer and manufacturing capacity that supports them. Stocks in this theme often move together on news about clinical trial results, international partnerships, or regulatory milestones.

8 companies · 5 up · 1 flat · 2 down

Traded value
₩218B
Value vs 20-day average
0.76×
Top gainer
Hanmi Pharm
+5.42%
Largest company
Samsung Biologics
₩64T

Companies in this theme

CompanyPriceDailyTraded valueMarket capNPS
Samsung Biologics207940 · KOSPI
₩1,372,000−0.15%₩69B₩64T6.88%
Alteogen196170 · KOSDAQ
₩223,000+2.06%₩53B₩16T2.68%
Yuhan000100 · KOSPI
₩77,300−3.38%₩27B₩5.7T6.83%
Hanmi Pharm128940 · KOSPI
₩369,500+5.42%₩42B₩4.7T9.61%
LigaChem Biosciences141080 · KOSDAQ
₩66,200+3.60%₩13B₩2.5T4.99%
ABL Bio298380 · KOSDAQ
₩41,800+2.33%₩13B₩2.3T4.02%
Yuhan Pref.000105 · KOSPI
₩65,2000.00%₩66M₩75B—
Oncocross382150 · KOSDAQ
₩3,145+1.13%₩64M₩41B—

Source: KRX statistical information